Background: Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose-limiting toxicities (DLTs), maximum tolerated or recommended phase 2 dose (MTD/RP2D), and pharmacokinetics (PK) of eribulin in children with refractory or recurrent solid (excluding central nervous system) tumors.
INTRODUCTION
Microtubule-targeting agents (MTAs) are among the most commonly used and effective drugs in the treatment of pediatric malignancies. 1 They exert their effects by binding to distinct sites on -tubulin 2 and ultimately either inhibit (destabilize) or promote (stabilize) its polymerization with -tubulin. 3 Vinca alkaloids (vincristine, vinblastine, vindesine, and vinorelbine), bind to the vinca domain located adjacent to the GTP binding site on -tubulin and destabilize the microtubule structure. 4 The role of vincristine in multimodal chemotherapy regimens is unparalleled in pediatric oncology practice with US Food and Drug Administration (FDA) approvals for the treatment of pediatric leukemia, lymphoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, and other soft tissue sarcomas. 5 Despite its widespread antitumor activity, peripheral neuropathy and tumor resistance are inherent limitations to its use. Vincristine-related neuropathy has led to a largely empiric dosing cap. 6 As a result, patients, particularly older children and adolescents, may receive a suboptimal dose contributing to an inferior outcome for diseases where vincristine plays an important role in frontline therapy. 7 Microtubule-stabilizing agents such as the taxanes (paclitaxel and docetaxel) and the epothilone ixabepilone, which after binding totubulin cause the creation of stable, nonfunctional tubule bundles, are active against a broad range of adult malignancies. 8, 9 In addition, ixabepilone is active in paclitaxel resistant tumors. 10 However, the antitumor activity of these microtubule-stabilizing agents in children has been disappointing. [11] [12] [13] The ineffectiveness of these agents in pediatric malignancies has several potential explanations, including the distinct histological origins of childhood cancer compared to carcinomas in adults, possible age-specific mechanisms of taxane and epothilone resistance, and the inability of these drugs to bind to certain -tubulin isotypes that may be of particular importance in pediatric cancers. 14 Eribulin mesylate (E7389) is a novel antimitotic agent that is a synthetic analog of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. 15 Like other antimitotic agents, eribulin inhibits cancer cell proliferation primarily via the induction of irreversible cell cycle arrest at G2/M through disruption of the mitotic spindles and initiation of apoptosis. However, eribulin is mechanistically unique. Like vinca alkaloids, eribulin is a microtubule-destabilizing agent, but unlike all known MTAs, eribulin only inhibits microtubule growth while having no effect on microtubule shortening. In addition, eribulin can promote the formation of nonproductive tubulin aggregates, reducing the pool of microtubule building blocks. 16 Eribulin is metabolized primarily by cytochrome P450 3A4 and is a substrate for the P-glycoprotein (P-gp) drug efflux pump; however, it maintains full in vitro activity against cancer cells that are taxane-resistant due totubulin mutations. 17 It has been extensively studied in adult human subjects and is FDA approved for breast cancer 18 and liposarcoma 19 at a dose of 1.4 mg/m 2 administered intravenously on days 1 and 8 of a 21-day cycle. 20 In adults treated with eribulin, the dose-limiting toxicities (DLTs) were neutropenia and febrile neutropenia. Other grade ≥ 3 toxicities related to eribulin included fatigue, muscle weakness, sensory neuropathy, hyperglycemia, hypophosphatemia, nausea, and vomiting. 21 In adults receiving eribulin doses of 0.25-4.0 mg/m 2 , the pharmacoki- 
MATERIALS AND METHODS

Patient eligibility
Patients >6 months and <18 years of age with measurable or evalu- A separate cohort was included for children 6-12 months of age, with age-specific organ function criteria, definitions of toxicity, and modification of required blood sampling for research studies (however, this cohort failed to enroll any patients and was subsequently closed for lack of accrual). Secondary to eribulin being a strong P-gp substrate with poor central nervous system (CNS) penetration being noted in preclinical studies, 24 patients with CNS tumors or tumors with CNS metastases were excluded; as were patients with bone marrow metastasis, uncontrolled infections, viral hepatitis, or patients with ≥grade 1 peripheral sensory or motor neuropathy graded according to the modified ("Balis") Pediatric Scale of Peripheral Neuropathies. 25 This trial was approved by the National Cancer Institute Central Institutional Review Board. Written informed consent and assent, as appropriate, were obtained in accordance with federal and institutional guidelines.
Drug administration
Eribulin mesylate (HAVALEN TM , Eisai, Inc., Woodcliff Lake, NJ) was 
Study design
This dose escalation study utilized a rolling six design. 26 Briefly, up to six patients were enrolled concurrently at the starting dose. Enrollment to subsequent dose levels was determined by the number of enrolled patients, the number with DLTs, and the number at risk for a DLT.
Toxicity was graded according to the Common Terminology Criteria for Adverse Events version 4.0 (http://ctep.cancer.gov). Early DLTs (prior to administration of the day 8 eribulin dose) were described previously (Section 2.2). Other hematologic DLTs were defined as grade 4 neutropenia for >7 days; grade 4 thrombocytopenia on two separate days, or requiring a platelet transfusion on two separate days, within a 7-day period; or myelosuppression that caused a delay of >14 days between treatment cycles. Nonhematologic DLTs were defined as grade 3 or 4 nonhematologic toxicities attributable to eribulin with the exclusion of grade 3 nausea and vomiting of fewer than 3 days duration, grade 3 transaminase elevation that returned to grade ≤ 1 or baseline prior to the time for the next treatment cycle, grade 3 fever or infection, or grade 3 electrolyte abnormalities responsive to oral supplementation. A nonhematologic toxicity that caused a delay of ≥14 days between treatment cycles was also considered a DLT. For patients <12 months of age, any grade ≥ 2 nonhematologic toxicity attributable to the study drug was considered a DLT.
Any patient who experienced a DLT at any time during the protocol therapy was evaluable for adverse events. Patients without DLTs who received 100% of the total prescribed cycle dose (i.e. received both, dose on day 1 and day 8 or 11) per protocol guidelines and had the appropriate toxicity monitoring studies performed were also evaluable for toxicity assessment and the primary study objective. The MTD was the maximum dose at which less than one-third of patients experienced a DLT during cycle 1 of therapy.
Tumor response was determined using Response Evaluation Criteria in Solid Tumors v1.1. 27
Study evaluations
Patient history, physical examination, and laboratory studies were 
Pharmacokinetic studies
Blood samples (3 ml) for eribulin mesylate pharmacokinetic studies were collected at a site distant from the infusion site and placed into prechilled sodium heparin vacutainer tubes prior to the day 1 dose and then 10 (±5) min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 24 hr, 48 hr, and 72 hr after the infusion. A PK sample was also collected at either 96 or 120 hr after the end of the day 1 infusion, just prior to the day 8 or11 dose and 10 (±5) min after the day 8 or 11 dose. Serum was separated by centrifugation at 2,500 × g relative centrifugal force for 15 min at 4 • C, transferred into polypropylene tubes, and stored at -70 • C until shipment on dry ice.
Pharmacokinetic analysis for eribulin mesylate in plasma samples was conducted by Eisai, Inc. using a validated high-performance liquid chromatography assay with tandem mass spectrometry detection.
Eribulin pharmacokinetic parameters were estimated using Phoenix 
RESULTS
Patient characteristics
From August 11, 2014 to December 14, 2016, 23 patients were enrolled onto the study, all of whom were eligible (Table 1) . Twentytwo patients were dosed with eribulin. Subjects had a median age of 14 years (range 3-17 years) and had 12 distinct solid tumor diagnoses.
All patients had received prior multi-agent chemotherapy (median, 2 regimens; range, 1-5 regimens) and thirteen had prior radiation therapy.
Toxicities
Twenty subjects were evaluable for toxicity assessment; two were not evaluable for toxicity because the required study observations were not obtained, and one did not receive eribulin and was not, therefore, evaluable for either toxicity or disease response. Seventeen children received eribulin at one of three dose levels as part of the escalation cohort, while an additional three children received eribulin in the PK expansion cohort. During the dose escalation component of the trial, three subjects experienced a first cycle DLT (Table 2) , with a single additional subject experiencing a DLT during cycle 2. Cycle 1 DLTs (Table 2) As a conservative approach, focused attention was given to cardiac electrophysiology during this study due to a minor increase in the QTc noted in adult subjects receiving eribulin. 28 In 22 subjects who received at least one dose of eribulin and who had at least one set of pre-and post-dose EKGs, the baseline mean QTc was 419 msec (standard deviation 20 msec). After the first dose of eribulin, four subjects experienced grade 1 prolonged QTc (450-480 msec) and one had grade 2 prolonged QTc (481-500 msec). All subjects who experienced QTc prolongation subsequently had their QTc return to baseline.
Pharmacokinetics
The Pharmacokinetics of eribulin mesylate was studied in 22 patients during cycle 1. The plasma concentration versus time profile for patients treated at the 1.4 mg/m 2 dose level is illustrated in Figure 1 and summary statistics for parameter estimates across all dose levels are summarized in Table 5 . There was heterogeneity in maximum concentration and AUC values ( Figures 1A and 1B , Table 5 ). Given the wide variability and small dose range, dose proportionality was difficult to accurately assess. However, in this population, there was no statistically significant difference in clearance with increasing dose levels (P = 0.6350). Overall, the median terminal half-life of eribulin was Attribution, as related to eribulin for all toxicities listed, was definite, possible, or probable only.
to eribulin than subjects who did not (n = 12), no parameter met sta- 
Response
Of the 22 subjects evaluable for response, one at dose level 1 
DISCUSSION
This pediatric phase 1 trial demonstrates that eribulin mesylate was well tolerated in children with refractory or recurrent solid tumors and established a RP2D of 1.4 mg/m 2 /dose administered intravenously on days 1 and 8 of a 21-day cycle. This is the recommended dose in adult patients and, similar to the adult experience, the major DLT in children was neutropenia with common other significant toxicities including nausea and vomiting. Only minor prolongations in QTc that were not of clinical significance were observed. Any grade fatigue as an eribulin-related adverse event was less commonly reported in this study of children (30%) than has been reported in adults (∼50%). 18, 19, 29, 30 In addition, adult studies have consistently reported peripheral neuropathy in one-quarter of subjects; however, using pediatric specific neuropathy grading, there were no reports of peripheral neuropathy in children in this study. 19, 29, 30 These data suggest that certain aspects of drug tolerance may be disparate in children when compared to adults. The decrease in nonhematological toxicity compared to adults may, in part, be related to the increased clearance of eribulin in children less than 12 years of age or potentially represents a pharmacodynamic difference.
Pharmacokinetics were highly variable over the dose range studied with a median terminal half-life of 39.6 hr. These data are fairly consistent with those from adult studies. 31, 32 We did find that there is an age dependent difference in body surface area corrected clearance when young children (≤12 years old) were compared to older children and adolescents. While our older child cohort had a clearance that was similar to adults (1.3-2.3 l/h/m 2 ), 31 our subjects ≤12 years old had a somewhat higher clearance of 2.4 l/h/m 2 . Possible confounders to this analysis include the uneven distribution of subjects by age cohort in each dose level, intrinsic to a phase 1 study, and the fact that since eribulin is a lipophilic drug, the lower clearance in older children could be affected by the higher percentage of body fat generally found in older children.
However, this suggests that studies of increased dosing in younger patients to ensure similar drug exposure to older patients might be TA B L E 4 All nonhematologic toxicities a related to protocol therapy observed in evaluable patients (n = 20) considered. While previous studies in adults have shown that the incidence of neutropenia increases with dose and maximum exposure, 31, 32 we showed only a trend towards statistical significance in the major exposure parameters between our subjects who experienced grade 4 neutropenia and those who did not. 33 Consistent with these data, 33 none of our nine subjects with osteosarcoma achieved any observable benefit.
Recent in vitro investigations have shown that eribulin induces changes in tumor biology beyond its established role in microtubule targeting. In breast tumors, leiomyosarcoma, and liposarcoma xenografts and cell lines, eribulin has been shown to modify gene expression, induce tumor cell differentiation, and cause tumor vasculature remodeling, all leading to cancer regression. [34] [35] [36] This tumor vasculature remodeling is thought to explain recent data demonstrating tumor eribulin exposures 20-30 times that seen concurrently in the plasma in xenograft mice. 37 Furthermore, a set of 26 microRNAs was discovered to differentiate responders and nonresponders in a recent EORTC phase 2 study of eribulin in adults with various soft tissue sarcomas. 38 Together, these data suggest that eribulin mesylate may be a targeted agent and highly effective in a select subset of tumor types. Our study supports the continued exploration of the potential benefit of eribulin mesylate both alone and in combination therapy in children with cancer.
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